Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial

Published:2021-09 Issue:9 Volume:22 Page:1275-1289
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Monk Bradley J,Colombo Nicoletta,Oza Amit M,Fujiwara Keiichi,Birrer Michael J,Randall Leslie,Poddubskaya Elena V,Scambia Giovanni,Shparyk Yaroslav V,Lim Myong Cheol,Bhoola Snehalkumar M,Sohn Joohyuk,Yonemori Kan,Stewart Ross A,Zhang Xiaoxi,Perkins Smith Julia,Linn Carlos,Ledermann Jonathan A

Funder

Roche

Pfizer

Sanofi

AstraZeneca

Pfizer Inc Boulder

Merck KGaA

Boehringer Ingelheim

Russian Academy of Sciences

Novartis

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?;Herzog;Gynecol Oncol Res Pract,2017

3. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Ledermann;Ann Oncol,2013

4. Incorporation of bevacizumab in the primary treatment of ovarian cancer;Burger;N Engl J Med,2011

5. A phase 3 trial of bevacizumab in ovarian cancer;Perren;N Engl J Med,2011

Cited by 156 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-reported symptom burden and circulating cytokines undergoing chemotherapy: a pilot study in patients with ovarian cancer;Journal of Gynecologic Oncology;2025

2. Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFNβ induces an anti-tumor immune response in high grade serous ovarian cancer;Neoplasia;2024-11

3. Composition analysis and mechanism of Guizhi Fuling capsule in anti-cisplatin-resistant ovarian cancer;2024-09-11

4. Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach;Nature Reviews Clinical Oncology;2024-09-04

5. Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors;Cell;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3